Co-Founder, mytide therapeutics
Next-Generation Peptide Manufacturing Leveraging Process Specific Optimization and Machine Learning
Biological treatments have been playing an increasing in importance playing an increased roll within therapeutic advances over the past two decades. The utilization of synthetic peptides has been especially prevalent in diagnostics and personalized therapeutics, however, these fields have struggled with the slow pace of manufacturing due to bottlenecks in coupling, cleavage, and chromatography. Advances in laboratory automation have helped improve the productivity of expert scientists; however, these technologies have not been able to meet the demand for custom peptide sequences to enable rapid, cost-effective drug discovery, especially when compared to DNA synthesis. Inefficient synthesis techniques often take weeks, if not months, to produce the target molecule, becoming a major bottleneck in the drug discovery pipeline. Given that peptides are assembled from one reaction and a discrete number of building blocks, machine learning (ML) has the ability to drastically increase the speed of manufacturing by enabling sequence-specific optimization, significantly reducing the overall drug discovery time.
Mytide is leveraging process specific optimization within its Rapid Automated Computation, Coupling, Cleavage, and Chromatography Execution (RAC4E) platform to inform sequence-specific recipes. These models are enabled by closing the loop between data collection and manufacturing planning for each process step. Integrating optimization strategies into RAC4E serves as a foundation for efficient library development, leading the way towards high-throughput drug discovery pipelines using peptides.
Dale earned his PhD in automated continuous drug synthesis where he spanned both Mechanical Engineering and Chemical Engineering at MIT. He also completed his MEngM at MIT and BS at Maine Maritime Academy. In his research, he developed an array of flow chemistry platforms for the advanced synthesis of pharmaceuticals and advanced materials. At Mytide Therapeutics, Dale is leading a cross-disciplinary team of scientists, and engineers to overcome decades-long bottlenecks in peptide manufacturing. Increasing the speed, purity, and length of peptides promise to increase the rate of drug discovery and access to revolutionary biological treatment with the goal of positively impacting patients lives.